Cash, cash equivalents, and short-term investments were $279.8 million at March 31, 2026, compared to $317.0 million at December 31, 2025. Based on its current operating plans, Amylyx (AMLX) expects a cash runway into 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx announces launch of U.S. EAP for adults with PBH
- Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch
- Amylyx price target raised to $21 from $19 at Mizuho
- Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential
- Amylyx Highlights Pipeline Progress in Updated Corporate Presentation